CUAMC
MLYS icon

China Universal Asset Management Company’s Mineralys Therapeutics MLYS Stock Holding History

China Universal Asset Management Company’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Sell
13,130
-914
-7% -$25.1K 0.02% 297
2026
Q1 		$380K Buy
14,044
+1,148
+9% +$33.7K 0.03% 287
2025
Q4 		$468K Buy
12,896
+1,275
+11% +$51.1K 0.04% 264
2025
Q3 		$441K Sell
11,621
-1,469
-11% -$31.8K 0.04% 259
2025
Q2 		$177K Buy
13,090
+3,094
+31% +$44.8K 0.02% 320
2025
Q1 		$159K Sell
9,996
-557
-5% -$6.41K 0.01% 330
2024
Q4 		$130K Buy
10,553
+989
+10% +$12.9K 0.01% 368
2024
Q3 		$116K Buy
9,564
+3,732
+64% +$45.2K 0.01% 346
2024
Q2 		$68.2K Sell
5,832
-2,099
-26% -$26.4K 0.01% 332
2024
Q1 		$102K Buy
7,931
+3,181
+67% +$39.3K 0.01% 371
2023
Q4 		$40.9K Buy
+4,750
New +$37.3K 0.01% 388

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

China Universal Asset Management Company's MLYS Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Mineralys Therapeutics (MLYS) stake by 6.5% in Q2 2026, selling an estimated $25.1K and leaving 13,130 shares worth $354K. The position accounts for 0.02% of the portfolio, ranked #297.

China Universal Asset Management Company first reported a position in MLYS in Q4 2023 and has held it in 11 quarters since. The position peaked at $468K in Q4 2025. 95 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • China Universal Asset Management Company held 13,130 shares of Mineralys Therapeutics worth $354K as of Q2 2026.
  • China Universal Asset Management Company sold 914 Mineralys Therapeutics shares in Q2 2026, an estimated $25.1K.
  • Mineralys Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #297 holding.
  • China Universal Asset Management Company first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • China Universal Asset Management Company's Mineralys Therapeutics position peaked at $468K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.